Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Glycopeptide-Resistant Enterococcus faecium BM4416 Is a VanD-Type Strain with an Impaired d-Alanine:d-Alanine Ligase

Bruno Perichon, Barbara Casadewall, Peter Reynolds, Patrice Courvalin
Bruno Perichon
Unité des Agents Antibactériens, Institut Pasteur, 75724 Paris Cedex 15, France,and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Casadewall
Unité des Agents Antibactériens, Institut Pasteur, 75724 Paris Cedex 15, France,and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Reynolds
Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom, CB2 1QW
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Courvalin
Unité des Agents Antibactériens, Institut Pasteur, 75724 Paris Cedex 15, France,and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.44.5.1346-1348.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

VanD-type Enterococcus faecium BM4416 was constitutively resistant to vancomycin and to teicoplanin by synthesis of peptidoglycan precursors ending ind-alanyl–d-lactate. Like E. faecium BM4339, the only VanD-type strain described so far, BM4416 produced an impaired d-alanine:d-alanine ligase. Unlike for BM4339, which had a 5-bp insertion inddl, inactivation of the gene in BM4416 was due to insertion of IS19.

Acquired glycopeptide resistance in enterococci is due to the synthesis of peptidoglycan precursors ending in the depsipeptide d-alanyl–d-lactate (d-Ala–d-Lac) instead of the dipeptided-alanyl–d-alanine (d-Ala–d-Ala) (5). The former considerably reduces binding affinity of glycopeptides for their peptidoglycan targets (2). Inducible high-level resistance to both vancomycin and teicoplanin and inducible variable levels of resistance to vancomycin alone are due to acquisition of thevanA and vanB operons, respectively (1, 2). Recently, a new glycopeptide resistance gene cluster,vanD, has been characterized in Enterococcus faecium BM4339, which is resistant to intermediate levels of vancomycin and to low levels of teicoplanin (6, 10). The organization of the vanA, vanB, andvanD operons is similar. Three proteins are required for glycopeptide resistance: a ligase (VanA, VanB, or VanD) to form the depsipeptide d-Ala–d-Lac, a dehydrogenase (VanH, VanHB, or VanHD) to convert pyruvate into d-Lac (5), and ad,d-dipeptidase (VanX, VanXB, or VanXD) to hydrolyze the dipeptided-Ala–d-Ala synthesized by the chromosomald-Ala:d-Ala Ddl ligase (4, 6, 13, 14). A d,d-carboxypeptidase (VanY, VanYB, or VanYD), not essential for resistance in VanA strains (3), hydrolyzes the C-terminal d-Ala of the remaining pentapeptide. VanYD is distinct from VanY and VanYB since it displays higher identity with some penicillin-binding proteins than with VanY and VanYB and contains the motifs predicted to define the active sites of penicillin-binding proteins (6). A two-component regulatory system, encoded by the vanR or vanRBand vanS or vanSB genes, controls the expression level of the resistance genes. In BM4439, the first VanD-type strain that has been described, resistance is constitutively expressed despite the presence of the vanSD andvanRD genes (6). In this strain, a 5-bp insertion in the 5′ part of the ddl gene is responsible for inactivation of Ddl and accounts for the lack of precursors terminating in d-Ala–d-Ala (6).

E. faecium BM4416 was isolated from a stool specimen of a 59-year-old male treated with vancomycin after a liver transplant for alcoholic cirrhosis. This strain was resistant to vancomycin (MIC = 128 μg/ml) and to teicoplanin (MIC = 64 μg/ml); it was also resistant to erythromycin, penicillin G, and high levels of streptomycin.

BM4416 was identified as E. faecium by a PCR assay using primers specific for genes encoding d-Ala:d-Ala ligases in enterococci (7). A PCR product was obtained only with the primer pair specific for the E. faecium ddl gene, but the length of the amplified fragment, approximately 2,100 bp, exceeded the expected length of 1,077 bp. Species identification was confirmed by PCR using two pairs of primers (8FPL-806R and 515FPL-13B) located in consensus sequences of rrs coding for 16S rRNA (11, 12). Nucleotide sequences of the fragments amplified from BM4416 total DNA were identical to those from a control strain,E. faecium BM4107. PCR primers specific for resistance genesvanA, vanB, vanC-1, vanC-2, and vanD (7, 10) indicated that BM4416 was of glycopeptide resistance genotype vanD.

The cytoplasmic peptidoglycan precursors of E. faeciumBM4416 grown with (4 μg/ml) or without vancomycin were analyzed as described previously (13) (Table1). Strain BM4416 mainly produced UDP-MurNAc-pentadepsipeptide (69%) terminating ind-Ala–d-Lac, UDP-MurNAc-tetrapeptide (24%), and UDP-MurNAc-tripeptide (7%). No significant amounts of UDP-MurNAc-pentapeptide were found (<1%). There were no differences between the peptidoglycan precursors produced from uninduced and induced cells. The precursors synthesized by BM4416 were qualitatively and quantitatively similar to those of E. faecium BM4339. As in E. faecium BM4339, glycopeptide resistance was constitutively expressed.

View this table:
  • View inline
  • View popup
Table 1.

Cytoplasmic peptidoglycan precursors synthesized byE. faecium BM4416a

Organization of the vanD operon in BM4416 was determined by PCR mapping (Fig. 1). Several pairs of primers, specific for each gene of the BM4339 vanD operon, were used in PCR experiments (Table 2). The PCRs gave fragments with the expected size, indicating that all the genes constituting the vanD operon were present and in the same order as in BM4339.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

PCR mapping of the vanD operon. Open arrows represent coding genes. Horizontal bars depict the PCR products. Arrowheads indicate direction of DNA synthesis. The sequences of the primers are given in Table 2.

View this table:
  • View inline
  • View popup
Table 2.

Oligodeoxynucleotides used for gene mapping

The vanD gene clusters were assigned to a chromosomal location in BM4416 and in BM4339 by contour-clamped homogeneous electric field gel electrophoresis. Agarose plugs were prepared and digested according to the manufacturer's recommendations (37°C, 3 h, 0.01 U) with I-CeuI, an intron-encoded endonuclease specific for rRNA genes (9). Fragments were separated on a 0.8% agarose gel using a CHEF-DRIII system (Bio-Rad Laboratories, Hercules, Calif.) under the following conditions: total migration, 24 h; initial pulse, 60 s; final pulse, 120 s; voltage, 6 V/cm; included angle, 120°; and temperature, 14°C. Fragments were transferred to a nitrocellulose sheet and hybridized (i) to an α-32P-labeled 16S rRNA (rrs) probe obtained by amplification of an internal portion of the rrs gene with primers RW01 and DG74 (8) and (ii) to a vanHDDXD probe obtained by PCR with primers HD1 and XD2 (Fig. 1 and Table 2). Therrs probe hybridized with five and four I-CeuI fragments from BM4416 and BM4339, respectively, and thevanHDDXD probe cohybridized with a 380-kb fragment from BM4416 and a 330-kb fragment from BM4339. These data indicate a chromosomal location for the vanD resistance operon in both strains and that the two isolates are distinct.

d,d-Peptidase activities in E. faecium BM4416 were assayed in enzyme extracts from E. faecium BM4416 prepared as described previously (4). Enzyme assays were performed with the S100 and C100 fractions of uninduced or induced (vancomycin concentration of 8, 16, or 64 μg/ml) cultures of E. faecium BM4416 (Table 3). Weakd,d-dipeptidase activity (VanXD) was found in the cytoplasmic extracts from vancomycin-induced or uninduced cells (Table 3). This is in contrast with strain BM4339, in which no VanX activity was detected (13). The difference in regulation of production of VanXD activity in these strains is currently under study. The amounts of d,d-carboxypeptidase (VanYD) activity found in membrane extracts of BM4416 and BM4339 were similar, and there were no differences between induced and uninduced cultures (Table 3) (10). As observed previously in BM4339, the VanYD activity of BM4416 was completely inhibited by penicillin G (10 mM).

View this table:
  • View inline
  • View popup
Table 3.

d,d-Peptidase activities in extracts fromE. faecium BM4416

The unexpected length of the PCR product obtained with primers specific for the E. faecium ddl gene, the presence of UDP-MurNAc-tripeptide in the pool of peptidoglycan precursors, and the absence of pentapeptide were compatible with the fact that BM4416 produced an impaired d-Ala:d-Ala ligase. Amplification by PCR of the entire ddl gene with specific primers (Y. Gholizadeh et al., unpublished data) gave rise to a 2,100-bp fragment which was cloned into PCR2.1 (Invitrogen, Leek, The Netherlands) and sequenced. An insertion sequence, designated IS19, of 1,038 bp was found in the middle of the gene (Fig.2). Insertion of the element generated a 9-bp (TATCAATAA) duplication of target DNA corresponding to nucleotides 762 to 770 of the ddl gene. IS19 was flanked by 21-bp perfect inverted repeats and contained an open reading frame which exhibited 39% identity with the structural gene for a putative transposase in IS982 from Lactococcus lactis (15). The presence of this genetic element accounts for the lack of synthesis of functional Ddl in E. faecium BM4416. As found for BM4339, thed-Ala:d-Ala ligase is not functional in BM4416. Constitutive expression of the resistance pathway, leading to production of modified precursors, allows growth of BM4416 in the absence of glycopeptides.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Sequence of IS19. The deduced amino acid sequence of the putative transposase is shown below the nucleotide sequence. The 21-bp perfect inverted repeats are indicated by arrows. The 9-bp duplication at the insertion site is indicated in bold characters. Putative −35 and −10 promoter regions and the putative ribosome-binding site (rbs) are indicated.

Resistance to glycopeptides in E. faecium BM4416 was due to synthesis of late peptidoglycan precursors ending ind-Ala–d-Lac. Constitutive resistance was encoded by a vanD operon closely related to that of E. faecium BM4339 and also located in the chromosome. Surprisingly, both VanD-type strains described so far produce an inactivatedd-Ala:d-Ala ligase due to an insertion in theddl gene. Differences in the levels of glycopeptide resistance of the two clinical isolates could be due to differences in the two-component regulatory systems or in individual resistance gene regulation.

ACKNOWLEDGMENTS

We thank J. Conly for the gift of strain BM4416.

This work was supported in part by a Bristol-Myers Squibb Unrestricted Biomedical Research Grant in Infectious Diseases and by the “Programme de Recherche Fondamentale en Microbiologie, Maladies Infectieuses et Parasitaires” from the Ministère de l'Education Nationale, de la Recherche et de la Technologie.

FOOTNOTES

    • Received 30 July 1999.
    • Returned for modification 26 November 1999.
    • Accepted 19 January 2000.
  • Copyright © 2000 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Arthur M.,
    2. Molinas C.,
    3. Depardieu F.,
    4. Courvalin P.
    Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 175 1993 117 127
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Arthur M.,
    2. Reynolds P. E.,
    3. Courvalin P.
    Glycopeptide resistance in enterococci. Trends Microbiol. 4 1996 401 407
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Arthur M.,
    2. Depardieu F.,
    3. Cabanié L.,
    4. Reynolds P. E.,
    5. Courvalin P.
    Requirement of the VanY and VanX d,d-peptidases for glycopeptide resistance in enterococci. Mol. Microbiol. 30 1998 819 830
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Arthur M.,
    2. Depardieu F.,
    3. Reynolds P.,
    4. Courvalin P.
    Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci. Mol. Microbiol. 21 1996 33 44
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Bugg T. D. H.,
    2. Wright G. D.,
    3. Dutka-Malen S.,
    4. Arthur M.,
    5. Courvalin P.,
    6. Walsh C. T.
    Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30 1991 10408 10415
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Casadewall B.,
    2. Courvalin P.
    Characterization of the vanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339. J. Bacteriol. 181 1999 3644 3648
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Dutka-Malen S.,
    2. Evers S.,
    3. Courvalin P.
    Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33 1995 24 27
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Greisen K.,
    2. Loeffelholz M.,
    3. Purohit A.,
    4. Leong D.
    PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid. J. Clin. Microbiol. 32 1994 335 351
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Liu S. L.,
    2. Hessel A.,
    3. Sanderson K. E.
    Genomic mapping with I-Ceu I, an intron-encoded endonuclease specific for genes for ribosomal RNA, in Salmonella spp., Escherichia coli, and other bacteria. Proc. Natl. Acad. Sci. USA 90 1993 6874 6878
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Perichon B.,
    2. Reynolds P.,
    3. Courvalin P.
    VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob. Agents Chemother. 41 1997 2016 2018
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Relman D. A.,
    2. Loutit J. S.,
    3. Schmidt T. M.,
    4. Falkow S.,
    5. Tompkins L. S.
    The agent of bacillary angiomatosis—an approach to the identification of uncultured pathogens. N. Engl. J. Med. 323 1990 1573 1580
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Relman D. A.,
    2. Schmidt T. M.,
    3. MacDermott R. P.,
    4. Falkow S.
    Identification of the uncultured bacillus of Whipple's disease. N. Engl. J. Med. 327 1992 293 301
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Reynolds P. E.,
    2. Depardieu F.,
    3. Dutka-Malen S.,
    4. Arthur M.,
    5. Courvalin P.
    Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of d-alanyl–d-alanine. Mol. Microbiol. 13 1994 1065 1070
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Wu Z.,
    2. Wright G. D.,
    3. Walsh C. T.
    Overexpression, purification, and characterization of VanX, a d,d-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry 34 1995 2455 2463
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Yu Z.,
    2. Mierau I.,
    3. Mars A.,
    4. Johnson E.,
    5. Dunny G.,
    6. McKay L. L.
    Novel insertion sequence-like element IS982 in lactococci. Plasmid 33 1995 218 225
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Glycopeptide-Resistant Enterococcus faecium BM4416 Is a VanD-Type Strain with an Impaired d-Alanine:d-Alanine Ligase
Bruno Perichon, Barbara Casadewall, Peter Reynolds, Patrice Courvalin
Antimicrobial Agents and Chemotherapy May 2000, 44 (5) 1346-1348; DOI: 10.1128/AAC.44.5.1346-1348.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Glycopeptide-Resistant Enterococcus faecium BM4416 Is a VanD-Type Strain with an Impaired d-Alanine:d-Alanine Ligase
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Glycopeptide-Resistant Enterococcus faecium BM4416 Is a VanD-Type Strain with an Impaired d-Alanine:d-Alanine Ligase
Bruno Perichon, Barbara Casadewall, Peter Reynolds, Patrice Courvalin
Antimicrobial Agents and Chemotherapy May 2000, 44 (5) 1346-1348; DOI: 10.1128/AAC.44.5.1346-1348.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Enterococcus faecium
Peptide Synthases
vancomycin resistance

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596